Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Potential Theranostic Boron Neutron Capture Therapy Agents as Multimodal Radiopharmaceuticals
Authors
Keywords
-
Journal
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
Volume -, Issue -, Pages -
Publisher
Mary Ann Liebert Inc
Online
2022-04-15
DOI
10.1089/cbr.2021.0276
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunobiology of Melanoma
- (2021) Yee Peng Phoon et al. CLINICS IN PLASTIC SURGERY
- Targeted melanoma radiotherapy using ultrasmall 177Lu-labeled α-melanocyte stimulating hormone-functionalized core-shell silica nanoparticles
- (2020) Xiuli Zhang et al. BIOMATERIALS
- Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): An open-label phase II trial
- (2020) Katsumi Hirose et al. RADIOTHERAPY AND ONCOLOGY
- Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting
- (2019) Jianquan Yang et al. MOLECULAR PHARMACEUTICS
- Functionalized 198Au nanoparticles for targeted cancer therapy
- (2019) Rubel Chakravarty et al. NUCLEAR MEDICINE AND BIOLOGY
- Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma
- (2019) Mengshi Li et al. MOLECULAR PHARMACEUTICS
- Increasing molar activity by HPLC purification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16/F1 melanoma xenograft model
- (2019) Jan Lennart von Hacht et al. PLoS One
- A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda
- (2019) Jia Luo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Melanoma-Targeting Property of Y-90-Labeled Lactam-Cyclized α-Melanocyte-Stimulating Hormone Peptide
- (2019) Jingli Xu et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Boron neutron capture therapy of cancer: Critical issues and future prospects
- (2019) Tai‐Ze Yuan et al. Thoracic Cancer
- Boron nitride nanotubes radiolabeled with 153Sm and 159Gd: Potential application in nanomedicine
- (2019) Wellington Marcos da Silva et al. APPLIED RADIATION AND ISOTOPES
- Theranostic radiopharmaceuticals: established agents in current use
- (2018) James R Ballinger BRITISH JOURNAL OF RADIOLOGY
- Melanoma Imaging Using 18F-Labeled α-Melanocyte-Stimulating Hormone Derivatives with Positron Emission Tomography
- (2018) Chengcheng Zhang et al. MOLECULAR PHARMACEUTICS
- Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?
- (2016) David Rizzieri CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A Novel Peptide for Simultaneously Enhanced Treatment of Head and Neck Cancer and Mitigation of Oral Mucositis
- (2016) Peili Chen et al. PLoS One
- Automated electrophilic radiosynthesis of [18F]FBPA using a modified nucleophilic GE TRACERlab FXFDG
- (2015) Severin Mairinger et al. APPLIED RADIATION AND ISOTOPES
- Advances in boron neutron capture therapy (BNCT) at kyoto university - From reactor-based BNCT to accelerator-based BNCT
- (2015) Yoshinori Sakurai et al. JOURNAL OF THE KOREAN PHYSICAL SOCIETY
- Accelerator based epithermal neutron source
- (2015) S. Yu. Taskaev PHYSICS OF PARTICLES AND NUCLEI
- Tumor Targeting, Trifunctional Dendritic Wedge
- (2014) Ramin Dubey et al. BIOCONJUGATE CHEMISTRY
- Preparation and evaluation of carborane-derived inhibitors of prostate specific membrane antigen (PSMA)
- (2014) Mohamed E. El-Zaria et al. DALTON TRANSACTIONS
- CT Perfusion Can Predict Overexpression of CXCL8 (Interleukin-8) in Head and Neck Squamous Cell Carcinoma
- (2013) S.Y. Jo et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-closo-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-closo-Decaborate(2-) Reagent via Lysine Amines
- (2012) D. Scott Wilbur et al. BIOCONJUGATE CHEMISTRY
- Current status of boron neutron capture therapy of high grade gliomas and recurrent head and neck cancer
- (2012) Rolf F Barth et al. Radiation Oncology
- Reagents for Astatination of Biomolecules. 5. Evaluation of Hydrazone Linkers in211At- and125I-Labeledcloso-Decaborate(2-) Conjugates of Fab′ as a Means of Decreasing Kidney Retention
- (2011) D. Scott Wilbur et al. BIOCONJUGATE CHEMISTRY
- Carbaboranes as Pharmacophores: Properties, Synthesis, and Application Strategies
- (2011) Matthias Scholz et al. CHEMICAL REVIEWS
- Reagents for Astatination of Biomolecules. 3. Comparison ofcloso-Decaborate(2-) andcloso-Dodecaborate(2-) Moieties as Reactive Groups for Labeling with Astatine-211
- (2009) D. Scott Wilbur et al. BIOCONJUGATE CHEMISTRY
- Preparation and in vivo evaluation of radioiodinated closo-decaborate(2-) derivatives to identify structural components that provide low retention in tissues
- (2009) D. Scott Wilbur et al. NUCLEAR MEDICINE AND BIOLOGY
- Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
- (2008) Annette Beck-Sickinger et al. Anti-Cancer Agents in Medicinal Chemistry
- closo-Borane Conjugated Regulatory Peptides Retain High Biological Affinity: Synthesis ofcloso-Borane Conjugated Tyr3-Octreotate Derivatives for BNCT
- (2008) Thomas Betzel et al. BIOCONJUGATE CHEMISTRY
- Streptavidin in Antibody Pretargeting. 5. Chemical Modification of Recombinant Streptavidin for Labeling with the α-Particle-Emitting Radionuclides213Bi and211At
- (2007) D. Scott Wilbur et al. BIOCONJUGATE CHEMISTRY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started